These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8799514)

  • 1. Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions.
    Hussein Z; Fraser IJ; Lees KR; Muir KW; Lunnon MW; Hobbiger SF; Posner J
    Br J Clin Pharmacol; 1996 Jun; 41(6):505-11. PubMed ID: 8799514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tolerability, pharmacokinetics and pharmacodynamics of increasing intravenous doses of 619C89, a novel compound for the acute treatment of stroke, in healthy volunteers.
    Mercer AJ; Lamb RJ; Hussein Z; Hobbiger S; Posner J
    Ann N Y Acad Sci; 1995 Sep; 765():324-6. PubMed ID: 7486632
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety and tolerability of 619C89 after acute stroke.
    Muir KW; Hamilton SJ; Lunnon MW; Hobbiger S; Lees KR
    Cerebrovasc Dis; 1998; 8(1):31-7. PubMed ID: 9645979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized, double-blind, placebo-controlled ascending dose tolerance study of 619C89 in acute stroke.
    Muir KW; Lees KR; Hamilton SJ; George CF; Hobbiger SF; Lunnon MW
    Ann N Y Acad Sci; 1995 Sep; 765():328-9. PubMed ID: 7486634
    [No Abstract]   [Full Text] [Related]  

  • 5. Phase II clinical trial of sipatrigine (619C89) by continuous infusion in acute stroke.
    Muir KW; Holzapfel L; Lees KR
    Cerebrovasc Dis; 2000; 10(6):431-6. PubMed ID: 11070372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the inhibition of voltage activated calcium currents in rat cortical neurones by the neuroprotective agent 619C89.
    Stefani A; Hainsworth AH; Spadoni F; Bernardi G
    Br J Pharmacol; 1998 Nov; 125(5):1058-64. PubMed ID: 9846645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.
    Jönsson S; Cheng YF; Edenius C; Lees KR; Odergren T; Karlsson MO
    Clin Pharmacokinet; 2005; 44(8):863-78. PubMed ID: 16029070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A use-dependent sodium channel antagonist, 619C89, in reduction of ischemic brain damage and glutamate release after acute subdural hematoma in the rat.
    Tsuchida E; Harms JF; Woodward JJ; Bullock R
    J Neurosurg; 1996 Jul; 85(1):104-11. PubMed ID: 8683258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple-dose pharmacokinetics and safety of a potential memory-enhancing compound, CL 275,838, in healthy male volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1994 Jul; 34(7):748-53. PubMed ID: 7929869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
    Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
    J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability and pharmacokinetics of escalating doses of NXY-059 in healthy young and elderly subjects.
    Wemer J; Cheng YF; Nilsson D; Reinholdsson I; Fransson B; Lanbeck Vallén K; Nyman L; Eriksson C; Björck S; Schulman S
    Curr Med Res Opin; 2006 Sep; 22(9):1813-23. PubMed ID: 16968585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group.
    Albers GW; Atkinson RP; Kelley RE; Rosenbaum DM
    Stroke; 1995 Feb; 26(2):254-8. PubMed ID: 7831698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, tolerability and pharmacokinetics of MCI-186 in patients with acute ischemic stroke: new formulation and dosing regimen.
    Kaste M; Murayama S; Ford GA; Dippel DW; Walters MR; Tatlisumak T;
    Cerebrovasc Dis; 2013; 36(3):196-204. PubMed ID: 24135530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-dose safety and pharmacokinetics of a potential cognition-enhancing compound, CL 275,838, in healthy volunteers.
    Caccia S; Confalonieri S; Guiso G; Lucca U; Parma E; Guido M; Tettamanti M; Tiraboschi P; Spagnoli A
    J Clin Pharmacol; 1993 Sep; 33(9):845-50. PubMed ID: 8227482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
    Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
    Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of age, gender, and diurnal variation on the steady-state pharmacokinetics of BMS-181101, an antidepressant, in healthy subjects.
    Srinivas NR; Shyu WC; Gleason C; Schuster A; Greene DS; Barbhaiya RH
    Clin Pharmacol Ther; 1997 Oct; 62(4):408-16. PubMed ID: 9357392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations.
    Snoeck E; Piotrovskij V; Jacqmin P; Lins RL; Van Peer A; Danhof M; Woestenborghs R; Van Gool R; Dupont AG; Heykants J
    Eur J Clin Pharmacol; 1997; 53(1):57-63. PubMed ID: 9349931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion.
    Peng B; Dutreix C; Mehring G; Hayes MJ; Ben-Am M; Seiberling M; Pokorny R; Capdeville R; Lloyd P
    J Clin Pharmacol; 2004 Feb; 44(2):158-62. PubMed ID: 14747424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.